

Curriculum Vitae

Name: Krähenbühl Stephan

Date of Birth: November 29, 1953

Business address: Clinical Pharmacology & Toxicology
University Hospital
CH-4031 Basel
Switzerland
Tel: +41 61 265 47 35
Fax: +41 61 265 45 60
e-mail: Kraehenbuehl@uhbs.ch

Education

1968 - 1972: Gymnasium of Burgdorf, Berne, Switzerland

1972 - 1978: School of Pharmacy, University of Berne, Diploma 1978

October 1978 - October 1980: Ph.D. thesis in Pharmaceutical Sciences at the Central Chemistry Laboratory, University Hospital of Berne (Prof. C. Bachmann/Prof. J.P. Colombo)

1979 - 1985: School of Medicine, University of Berne, Diploma 1985

1985: M.D. at the Institute of Clinical Pharmacology of the University of Berne (Prof. J. Reichen)

January 1986: ECFMG, Berne

1981 - 1985: Head of the Hospital Pharmacy, Bezirksspital Niederbipp, Berne

1984 - 1989: Head of the Hospital Pharmacy, Bezirksspital Langnau, Berne

January 1986 - December 1986: Internship, Department of Internal Medicine, Bezirksspital Langnau, Berne (H.R. Hunziker, M.D.)

January 1987 - February 1989: Fellow, Institute of Clinical Pharmacology, University of Berne (Prof. J. Reichen/Prof. R. Preisig)

March 1989 - March 1991: Fellow und Senior Fellow, Department for Clinical Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, USA (Prof. E.P. Brass/Prof. C.L. Hoppel)

April 1991 - March 1993: Resident, Department of Internal Medicine, Inselspital, Berne (Prof. H. Studer and Prof. P.W. Straub)

April 1993 - March 1997: Senior Physician, Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Zürich (Prof. P. Meier-Abt)

April 1997 - September 1997: Senior Physician, Department of Internal Medicine, General Internal Medicine, Inselspital Berne (Prof. W. Straub, Prof. F. Frey)

October 1997 – December 1999: 1st Senior Physician, Clinical Pharmacology, University of Berne (Prof. J. Reichen and Prof. B.H. Lauterburg). Training in Clinical Pharmacology and in Hepatology

August 1998 – November 1998: Senior Physician, Department of Internal Medicine, General Internal Medicine, Inselspital, Berne (Prof. W. Straub, Prof. F. Frey)

January 2000 – till today: Head of the Division of Clinical Pharmacology & Toxicology and of the Institute of Clinical Pharmacy at the University Hospital and the University of Basel, Switzerland

January 2000 – December 2001: Attending Physician on the Clinics A and B (Internal Medicine) of the University Hospital Basel, Switzerland

January 2002 – June 2002: Interimistic Head of Clinic B (Internal Medicine) of the University Hospital of Basel

July 2002 – today: Chief Physician at the Clinics B (Internal Medicine) of the University of Basel

Professional Training and Experiences

April 1978: Swiss Federal Diploma in Pharmacy (University of Berne)

November 1985: Swiss Medical Diploma (University of Berne)

April 1993: Specialist for Internal Medicine (FMH)

May 1994: Specialist for Clinical Pharmacology (FMH)

October 1997: FAMH Title in Clinical Chemistry

April 1997-December 1999: Training in Hepatology (there is no title in Hepatology)

Scientific Training and Awards

November 1981: PhD in Pharmaceutical Sciences (University of Berne), Thesis: "Entwicklung eines neuen Enzymassays für die N-Acetylglutamat-Synthetase: Bestimmung der Enzymaktivität in Geweben von Ratte und Mensch sowie Untersuchung der kinetischen Eigenschaften von menschlichem, aufgereinigtem

Enzym."

December 1985: MD (University of Berne), Thesis:

"Defective bile acid transport in an animal model of defective debrisoquine hydroxylation."

May 1988: Young Investigator Award of the American Gastroenterology Association (AGA) for:

„Effect of secretin on bile formation in rats with cirrhosis of the liver: Structure-function relationship.,,

November 1993: Venia Legendi in the fields of Internal Medicine and Clinical Pharmacology (University of Zürich):

"Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention."

October 1996: Special award of the Swiss Society of Gastroenterology and Hepatology (SGGH) for:

„Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats.,,

October 1996: Special award of the Swiss Society of Gastroenterology and Hepatology (SGGH) for a poster presentation:

„Der Benzoessäuremetabolismus ist ein Mass für die mitochondriale Funktion in cholestatichen Ratten.,,

November 1997: Research award of the Swiss Society for Research in Surgery for:

„Benzoic acid metabolism reflects hepatic mitochondrial function in rats with long-term extrahepatic cholestasis.“

June 1998: Research award of the Swiss Society of Surgery for: „Rapid normalization of hepatic glycogen metabolism in rats with long-term bile duct ligation after biliodigestive anastomosis“

September 1999: Professor in the fields of Clinical Pharmacology and Internal Medicine, University of Berne

Since January 2000: Professor for Clinical Pharmacology/Toxicology and Internal Medicine, University of Basel

June 2005: Research award of the Swiss Society of Cardiology for: „Kinetics and dynamics of furosemide in healthy volunteers after oral or sublingual administration“

Grants

Swiss National Science Foundation and other Foundations

March 1989 - February 1991: Grant of the Swiss National Science Foundation for a stay abroad 100'000 CHF

*January 1994 - December 1996: Swiss National Science Foundation (32-37280.93)
325'000 CHF*

*February 1994: Foundation for Scientific Research at the University of Zürich 50'000
CHF*

*January 1997 - March 2000: Swiss National Science Foundation (31-46792.96)
290'000 CHF*

*January 1998 – December 2000: Swiss Research Foundation for Muscle Diseases
150'000 CHF*

*April 2000 - March 2003: Swiss National Science Foundation (3100-059812.99/1)
225'000 CHF*

April 2002 – March 2003: Swiss Foundation for Aging 50'000 CHF

*April 2003 – March 2006: Swiss National Science Foundation (3100-059812.03/1)
200'000 CHF*

January 2004: Novartis Foundation 50'000 CHF

*April 2006 – March 2009: Swiss National Science Foundation (310000-112483/1)
300'000 CHF*

Industry and Associations

Since 2000: Many grants from the Chemical and Pharmaceutical Industry (Astra-Zeneca, Braun, Novartis, Roche, RCC, Lonza) 1.5 Mio CHF for different research projects

Since 2005: Important participation (initiation of the projects, pivotal input in the conducting of the projects) in the funding of two professorships in the Dept. of Pharmaceutical Sciences of the University of Basel (Novartis Chair in Mechanistic and Systemic Toxicology, Clinical Pharmacy & Pharmacoepidemiology) ≈ 3 Mio CHF

Teaching

January 87 - March 93: Lectures in Clinical Pharmacology for medical and pharmaceutical students at the University of Berne (1989/90 break due to a stay abroad)

March 90 - March 91: Lectures and courses in Clinical Pharmacology for medical students at the Medical School of the Case Western Reserve University, Cleveland, Ohio, USA

April 1993 - March 1997: Lectures in Clinical Pharmacology for medical, dental medicine and pharmaceutical students at the University of Zürich

April 1994 - March 1997: Lectures in Hepatology for medical students at the University of Zürich

April 1997- December 1999: Lectures in Clinical Pharmacology for medical and dental medicine students at the University of Berne

April 1997 – December 1999: Group instructions for medical students (1st clinical year) at the University of Berne

Since 2000: Lectures in Clinical Pharmacology for medical and pharmacy students at the University of Basel

Since 2000: Lectures in basic and clinical toxicology for medical and pharmacy students at the University of Basel

Since 2000: Lectures in clinical nutrition for pharmacy students at the University of Basel

Since 2000: Lectures in clinical nutrition at the Swiss Federal Technical Institute in Zurich

Supervision of Dissertations (PhD and MD theses)

1988: Jürg Knuchel, Medizinische Fakultät, Universität Bern: Effect of secretin on bile formation in rats with cirrhosis of the liver: Structure-function relationship.

1989: Susanne Glauser, Veterinärmedizinische Fakultät, Universität Bern: Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte.

1997: Simona Berardi, Abteilung Biochemie, ETH Zürich: Functional and molecular characterization of carnitine transport in rat kidney cortex and skeletal muscle

1996: Walter Heuberger, Medizinische Fakultät, Universität Zürich: Increased urinary excretion of carnitine in patients treated with cisplatin

2001: Sabine Wächter, Departement Pharmazie, Universität Basel: Long-term administration of carnitine to humans: effect on skeletal muscle carnitine content and physical performance

2001: Corinne Lang, Abteilung Pharmazie, ETH Zürich: Characterization of hepatic glycogen and fat metabolism in rats and humans with liver disease

2002: Markus Spaniol, *Departement Pharmazie, Universität Basel*: Development and characterization of an animal model of carnitine deficiency

2002: Hilary Brooks, *Philosophisch-Naturwissenschaftliche Fakultät, Universität Basel*: The carnitine transporter OCTN2: just how important is it for carnitine transport

2003: Max Jakob, *Medizinische Fakultät, Universität Basel*: Dose adaptation of antineoplastic drugs in patients with liver disease.

2004: Karl Welzenbach, *Philosophisch-Naturwissenschaftliche Fakultät, Universität Basel*: Differential effects of low molecular weight inhibitors on the conformation and the immunologic function of the adhesion receptor LFA-1

2004: Laurence Vernez, *Philosophisch-Naturwissenschaftliche Fakultät, Universität Basel*: Analysis of Carnitine and Acylcarnitines in Biological Fluids and Application to a Clinical Study

2004: Tobias Flückiger, *Medizinische Fakultät, Universität Basel*: Benzodiazepin assoziierte Probleme in einer internistischen Klinik unter Berücksichtigung des Konsumes vor der Hospitalisation.

2004: Georg Meffert, *Medizinische Fakultät, Universität Basel*: Entwicklung einer Methode zum Nachweis mitochondrialer Kreatinkinase (Mi-CK) und ihre pathophysiologische Bedeutung im Energiestoffwechse der humanen Leber

2004: Lydia Tchambaz, *Philosophisch-Naturwissenschaftliche Fakultät, Universität Basel*: Dose Adaptation of Drugs in Patients with Liver Diseases

2004: Alexandra Rätz Bravo, *Philosophisch-Naturwissenschaftliche Fakultät, Universität Basel*: Importance of Drug-Drug Interactions in Drug Safety

2005: Priska Kaufmann, *Philosophisch-Naturwissenschaftliche Fakultät, Universität Basel*: A Small Dose of Toxicology: Role of Mitochondrial Dysfunction in Hepatic and Skeletal Muscle Toxicity.

2005: Anita Schnyder, *Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel*: In vitro and in vivo Drug Targeting using Biotinylated Immunoliposomes

2005: Anita Krähenbühl-Melcher, *Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel*: Hospital Drug Safety – Role of the Hospital Pharmacist

2005: Saskia Lüde, *Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel*: Hepatotoxicity of the Phytotherapeutics Kava Kava and Cimicifuga racemosa

2006: Jörg Indermitte, *Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel*: Potential Drug Interactions – Exposure and Management in Hospital and Ambulatory Settings

2006: *Mathieu Noyer, Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel: Murine c-erbB2: an oncogene that could be a target for vaccination therapy?*

2007: *Sabin Egger, Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel: Potential Risk Factors for Adverse Drug Reactions in Elderly Patients – Contributions to a safer Drug Prescribing.*

2007: *Vonbach Priska, Philosophisch-Naturwissenschaftliche Fakultät der Universität Basel: Drug-drug interactions in the hospital.*

Habilitations

2001: Dr. Christoph Meier, Medizinische Fakultät Basel

2003: Dr. Jörg Huwyler, Naturwissenschaftliche Fakultät, Universität Basel

2005: Dr. Raymond Schlienger, Medizinische Fakultät Basel

2005: Dr. Christian Burri, Naturwissenschaftliche Fakultät Basel

2005: Dr. Gabriele Weitz, Naturwissenschaftliche Fakultät Basel

2006: Dr. Kurt Hersberger, Naturwissenschaftliche Fakultät Basel

Memberships in Working Groups and Committees

January 1994 - March 1996: President of the working group 'medical subjects' within the project „reformation of the studies in pharmacy“

January 1995 - March 1997: Member of the Ethics Committee of the Department of Internal Medicine, University Hospital, Zürich

October 1997 – December 1999: Member of the Consultation Committee in the field of clinical questions about nutrition, Inselspital, Berne

January 1998 – December 1999: Member of the Ethics Committee, University of Berne, Medical School

January 1999 – December 2001: External Advisor of the Swiss National Health Authorities (IKS), Berne

Since January 2000: President of the Drug Surveillance Committee, University Hospital, Basel

Since January 2002: President of the Medical Experts Committee (MEC) of the Swiss National Health Authorities (Swissmedic)

Since January 2006: President of the succession committee for Prof. F. Bühler (pharmaceutical medicine at the University of Basel)

Memberships in Academic and Professional Societies

January 1994 - October 1998: Board member of the Working Group of the Swiss Association for the Study of the Liver (SASL)

August 1996 – July 1999: Member of the Scientific Committee of the European Association for the Study of the Liver (EASL)

May 1998 – April 2002: President of the Swiss Society of Clinical Pharmacology & Toxicology

Since January 2001: Member of the board of the Swiss Society of Pharmacology and Toxicology

May 2002 – April 2005: Member of the board of the Swiss Society of Clinical Pharmacology & Toxicology

Publications

Articles with Peer Review

1. Bachmann C, Krähenbühl S, Colombo JP, Schubiger G, Jaggi KH, Tönz O. N-Acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. *N Engl J Med* 1981;304:543
2. Colombo JP, Krähenbühl S, Bachmann C, Aeberhard P. N-Acetylglutamate synthetase: enzyme assay in human liver. *J Clin Chem Clin Biochem* 1982;20:325-329
3. Bachmann C, Krähenbühl S, Colombo JP. Purification and Properties of acetyl-CoA:L-glutamate N-acetyltransferase from human liver. *Biochem J* 1982;205:123-127
4. Reichen J, Krähenbühl S, Küpfer A, Sägesser H, Karlaganis, G. Defective bile acid transport in an animal model of defective debrisoquine hydroxylation. *Biochem Pharmacol* 1986;35:753-759
5. Krähenbühl S, Reichen J. Canalicular bile flow and bile salt secretion are maintained in rats with liver cirrhosis: further support for intact cell hypothesis. *J Hepatol* 1988;7:63-71.
6. Krähenbühl S, Stucki J, Reichen J. Mitochondrial function in carbon tetrachloride-induced cirrhosis in the rat. Qualitative and quantitative defects. *Biochem Pharmacol* 1989;38:1583-1588.
7. Krähenbühl S, Meier-Abt P, Reichen J. Taurocholate transport by liver plasma membrane vesicles is not altered in cirrhotic rats. *J Hepatol* 1989;9:1-9.
8. Knuchel J, Krähenbühl S, Zimmermann A, Reichen J. Effect of secretin on bile formation in rats with cirrhosis of the liver: Structure-function relationship. *Gastroenterology* 1989;97:950-957.
9. Krähenbühl S, Reichen J, Zimmermann A, Gehr P, Stucki J. Mitochondrial structure and function in CCl₄-induced cirrhosis in the rat. *Hepatology* 1990;12:526-532.
10. Krähenbühl S, Rey DB, Stabler S, Allen R, Brass EP. Increased hepatic mitochondrial capacity in rats with hydroxy-cobalamin[c-lactam]-induced methylmalonic aciduria. *J Clin Invest* 1990;86:2054-2061.
11. Krähenbühl S, Brass EP. Inhibition of hepatic propionyl-CoA synthetase activity by organic acids. Reversal of propionate inhibition of pyruvate metabolism. *Biochem Pharmacol* 1991;41:1015-1023.
12. Tandler B, Krähenbühl S, Brass EP. Unusual mitochondria in the hepatocytes of rats treated with a vitamin B₁₂ analogue. *Anatom Rec* 1991;231:1-6.

13. Krähenbühl S, Cheng M, Brass EP, Hoppel CL. Decreased activities of ubiquinol-ferricytochrome-c oxidoreductase (complex III) and ferrocycytochrome-c-oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin[c-lactam]-induced methylmalonic aciduria. *J Biol Chem* 1991;266:20998-21004.
14. Krähenbühl S, Weber FL Jr, Brass EP. Decreased hepatic glycogen content and accelerated response to starvation in rats with carbon tetrachloride-induced liver cirrhosis. *Hepatology* 1991;14:1189-1195.
15. Krähenbühl S, Brass EP. Fuel homeostasis and carnitine metabolism in rats with secondary biliary cirrhosis. *Hepatology* 1991;14:927-934.
16. Krähenbühl S, Minkler PE, Hoppel CL. Derivatization of isolated endogenous butyrobetain with 4'-bromophenacyl trifluoromethanesulfonate followed by high-performance liquid chromatography. *J Chromatogr Biomed Applic* 1992;573:3-10.
17. Krähenbühl S, Krähenbühl-Glauser S, Stucki J, Gehr P, Reichen J. Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. *Hepatology* 1992;15:1167-1172.
18. Krähenbühl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. *Hepatology* 1992;15:1160-1166.
19. Krähenbühl S, Reichen J. Adaptation of mitochondrial metabolism in liver cirrhosis: different strategies to maintain a vital function. *Scand J Gastroenterol* 1992;27(Suppl 193):90-96.
20. Krähenbühl S, Reichen J. Decreased hepatic glucose production in rats with carbon tetrachloride-induced liver cirrhosis. *J Hepatol* 1993;19:64-70.
21. Krähenbühl S, Raisin J, Herren T. Malignes neuroleptisches Syndrom unter Metoclopramid und Neuroleptica bei Anurie. *Schweiz Med Wschr* 1993;123:1359-1362.
22. Krähenbühl S, Grass P, Surve A, Kutz K, Reichen J. Pharmacokinetics and hemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. *Eur J Clin Pharm* 1993;45:247-253.
23. Herren T, Como F, Krähenbühl S, Wyss PA. Die Therapie der akuten Salicylatintoxikation. *Schweiz Med Wschr* 1993;123:1775-1783.
24. Hasler F, Krapf R, Brenneisen R, Bourquin D, Krähenbühl S. Determination of 18beta-glycyrrhetic acid in biological fluids from humans and rats by solid-phase extraction and high-performance liquid chromatography. *J Chromatogr Biomed Applic* 1993;620:73-82.

25. Krähenbühl S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. *Pharmac Ther* 1993;60:1-38.
26. Krähenbühl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. *Hepatology* 1994;19:471-479.
27. Krähenbühl S, Hasler F, Brenneisen R, Frey B, Frey F, Krapf R. Kinetics and dynamics of 18 β -glycyrrhetic acid in humans. *J Clin Endocrinol Metab* 1994;78:581-585.
28. Ambühl PM, Ballmer PE, Krähenbühl S. Fulminante Hepatitis: Pathogenese, Klinik und Management. *Schweiz Med Wochenschr* 1994;124:368-380.
29. Krähenbühl S, Talos C, Reichen J. Mechanisms of impaired hepatic fatty acid metabolism in rats with chronic bile duct ligation. *Hepatology* 1994;19:1272-1281.
30. Frenzer A, Gyr T, Schär H, Herren H, Krähenbühl S. Drillingsschwangerschaft mit HELLP Syndrom und transientem Diabetes insipidus. *Schweiz Med Wschr* 1994;124:687-691.
31. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. *Hepatology* 1994;20:1595-1601.
32. Friolet R, Hoppeler H, Krähenbühl S. Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. *J Clin Invest* 1994;94:1490-1495.
33. Krähenbühl S, Talos C, Wiesmann U, Hoppel CL. Development and evaluation of a spectrophotometric assay for complex III in isolated mitochondria, tissues and fibroblasts from rats and humans. *Clin Chim Acta* 1994;230:177-187.
34. Krähenbühl S, Hasler F, Krapf R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetic acid in humans and experimental animals. *Steroids* 1994;59:121-126.
35. Krähenbühl S, Mang G, Kupferschmidt H, Meier P, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal valproate-induced hepatotoxicity. *Gut* 1995;37:140-143.
36. Krähenbühl S, Marti U, Grant I, Garlick PJ, Ballmer PE. Characterization of mechanisms causing hypoalbuminemia in rats with long-term bile duct ligation. *J Hepatol* 1995;23:79-86.
37. Krähenbühl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Reversible QT prolongation with torsade de pointes in a patient with pimozide

- intoxication. Am J Med Sci 1995;309:315-316.
38. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in man. Clin Pharm Ther 1995;58:20-28.
 39. Berardi S, Hagenbuch B, Carafoli E, Krähenbühl S. Characterization of the endogenous carnitine transport and expression of a rat renal Na⁺-dependent carnitine transport system in *xenopus laevis* oocytes. Biochem J 1995;309:389-393.
 40. Krähenbühl S, Talos C, Lauterburg BH, Reichen J. Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology 1995;22:607-612.
 41. Stieger B, O'Neill B, Krähenbühl S. Characterization of L-carnitine transport by rat kidney brush border membrane vesicles. Biochem J 1995;309:643-647.
 42. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krähenbühl S. Rhabdomyolyse bei mit Simvastatin und Ciclosporin behandelten Patienten: Rolle der Aktivität des Cytochrom P450 Enzymsystems der Leber. Schweiz Med Wschr 1995;125:1342-1346.
 43. Frenzer A, Schubarth P, Soucek M, Krähenbühl S. Disappearance of a large mediastinal pseudocyst in a patient with chronic alcoholic pancreatitis after total parenteral nutrition. Eur J Gastroenterol Hepatol 1995;7:369-371.
 44. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, Krähenbühl S, Meier PJ. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Int Med 1995;123:598-600.
 45. Ha HR, Jinzhen C, Krähenbühl S, Follath F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 1996;49:309-315.
 46. Krähenbühl S, Smith-Gamble V, Hoppel CL. Pharmacokinetic interaction between diltiazem and nortriptyline. Eur J Clin Pharmacol 1996;49:417-419.
 47. Colombani P, Wenk C, Kunz I, Krähenbühl S, Kuhnt M, Arnold M, Frey-Rindova P, Frey W, Langhans W. Effects of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double-blind crossover field study. Eur J Appl Physiol 1996;73:434-439.
 48. Krähenbühl S, Schäfer T, Wiesmann U. Determination of the activities of the enzyme complexes of the electron transport chain in human fibroblasts. Clin Chim Acta 1996;253:79-90.
 49. Krähenbühl L, Talos C, Reichen J, Krähenbühl S. Progressive decrease in tissue glycogen content in rats with long-term cholestasis. Hepatology 1996;24:902-907.

50. Fattinger KE, Rentsch KM, Meier PJ, Dazzi H, Krähenbühl S. Safety of liver transplantation after fatal intoxication with the tricyclic antidepressant trimipramine. *Transplantation* 1996;62:1259-1262.
51. Krähenbühl S. Carnitine metabolism in chronic liver disease. *Life Sciences* 1996; 59:1579-1599.
52. Kupferschmidt H, Langenegger T, Krähenbühl S. Perikarditis bei chronisch entzündlicher Darmerkrankung. Grundkrankheit oder Nebenwirkung der Therapie?. *Schweiz Med Wschr* 1996;126:2184-2190.
53. Krähenbühl S, Reichen J. Carnitine metabolismus in patients with chronic liver disease. *Hepatology* 1996;25:148-153.
54. Ruesch S, Krähenbühl S, Kleinle-Stadges SI, Liechti-Gallat S, Schaffner T, Wermuth B, Weber J, Wiesmann UN. Combined 3-methylglutaconic and 3-hydroxy-3-methylglutaric aciduria with endocardial fibroelastosis and dilatative cardiomyopathy in a male and female sibling with partial deficiency of complex II/III in fibroblasts. *Enzyme Protein* 1996;49:321-329.
55. Krähenbühl L, Reichen J, Talos C, Krähenbühl S. Benzoic acid metabolism reflects hepatic mitochondrial function in rats with long-term extrahepatic cholestasis. *Hepatology* 1997;25:278-283.
56. Baerlocher KE, Steinmann B, Aguzzi A, Krähenbühl S, Roe CR, Vianey-Saban C. Short-chain acyl-CoA dehydrogenase (SCAD)-deficiency in a 16-year-old girl with severe muscle wasting and scoliosis. *J Inher Metab Dis* 1997;20:427-431.
57. Laubscher B, Janzer R, Krähenbühl S, Hirt L, Deonna T, Calame A. Ragged-red fibers and complex I deficiency in a neonate with arthrogryposis congenita. *Ped Neurol* 1997;17:249-251.
58. Mahler H, Pasi A, Kramer JM, Schulte P, Scoging AC, Bär W, Krähenbühl S. Fulminant liver failure in association with the emetic toxin of *bacillus cereus*. *N Engl J Med* 1997;336:1142-1148.
59. Ha HR, Follath F, Bloemhard Y, Krähenbühl S. Determination of saquinavir in human plasma by high-performance liquid chromatography. *J Chromatogr Biomed Applic* 1997;694:427-433.
60. Forestier M, Solioz M, Isbeki F, Talos C, Reichen J, Krähenbühl S. Hepatic mitochondrial proliferation in rats with secondary biliary cirrhosis: time course and mechanisms. *Hepatology* 1997;26:386-391.
61. Kleinle S, Schneider V, Wiesmann U, Krähenbühl S, Superti-Furga A, Reichen J, Liechti-Gallati S. Screening for human mitochondrial DNA rearrangements by long PCR-detection of two novel mtDNA rearrangements. *Hum Genet* 1997;100:643-650.

62. Ambühl PM, Ballmer PE, Krähenbühl S, Krapf R. Quantification and predictors of plasma volume expansion from mannitol treatment. *Intensive Care Med* 1997;23:1159-1164.
63. Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. *Br J Clin Pharmacol* 1998;45:355-359.
64. Krähenbühl L, Schäfer M, Krähenbühl S. Reversibility of hepatic mitochondrial damage in rats with long-term cholestasis. *J Hepatol* 1998;28:1000-1007.
65. Berardi S, Stieger B, O'Neill B, Krähenbühl S. Transport of butyrobetaine into rat liver plasma membrane vesicles. *Hepatology* 1998;28:521-525.
66. Kleinle S, Schneider V, Moosmann P, Brandner P, Krähenbühl S, Liechti-Gallati S. A novel mitochondrial tRNAPhe mutation inhibiting anticodon stem formation associated with a muscle disease. *Biochem Biophys Res Com* 1998;247:112-115.
67. Imoberdorf R, Krähenbühl S, Krapf R. Carnitinpalmitoyl Transferase II-Mangel: Klinik, Pathophysiologie und Therapie. *Schweiz Med Wschr* 1998;128:1024-1029.
68. Kronenberg A, Krähenbühl S, Zimmermann A, Streuli R. Schwerer hepatozellulärer Schaden nach Einnahme von Paracetamol und Clorzoxazon in therapeutischer Dosierung. *Schweiz Rundsch Med Prax* 1998;87:1356-1360.
69. Heuberger W, Berardi S, Jacky E, Pey P, Krähenbühl S. Increased excretion of carnitine in patients treated with cisplatin. *Eur J Clin Pharmacol* 1998;503-508.
70. Krähenbühl S, Menafoglio A, Giostra E, Gallino A. Serious interaction between mibefradil and tacrolimus. *Transplantation* 1998;66:1113-1115.
71. Wächter S, Krähenbühl L, Schäfer M, Krähenbühl S. The liver carnitine pool reflects alterations in hepatic fatty acid metabolism in rats with bile duct ligation before and after biliodigestive anastomosis. *J Hepatol* 1999;30:242-248.
72. Krähenbühl S, Willer B, Brühlmann P, Hoppeler H, Stucki G. Carnitine homeostasis in patients with rheumatoid arthritis. *Clin Chim Acta* 1999;279:35-45.
73. Krähenbühl S. Acarbose and acetaminophen – a dangerous combination ? *Hepatology* 1999;29:285-287.
74. Krähenbühl S, Kleinle S, Henz S, Leibundgut K, Liechti S, Zimmermann A, Wiesmann U. Microvesicular steatosis, hemosiderosis and rapid development of liver cirrhosis in a patient with Pearson's syndrome. *J Hepatol* 1999;31:550-555.
75. Krähenbühl L, Hagenbuch B, Berardi S, Schäfer M, Krähenbühl S. Rapid normalization of hepatic glycogen metabolism in rats with long-term bile duct ligation after biliodigestive anastomosis. *J Hepatol* 1999;31:656-663.

76. Willer B, Stucki G, Hoppeler H, Brühlmann P, Krähenbühl S. Effects of creatine supplementation on muscle weakness in patients with rheumatoid arthritis. *Rheumatology* 2000;39:293-298.
77. Brooks H and Krähenbühl S. Development of a new assay for complex I of the respiratory chain. *Clin Chem* 2000;46:345-350.
78. Berardi S, Stieger B, Hagenbuch B, Carafoli E, Krähenbühl S. Characterization of L-carnitine transport into rat skeletal muscle plasma membrane vesicles. *Eur J Biochem* 2000;267:1985-1994.
79. Krähenbühl L, Ledermann M, Lang C, Krähenbühl S. Relationship between hepatic mitochondrial functions *in vivo* and *in vitro* in rats with carbon tetrachloride-induced liver cirrhosis. *J Hepatol* 2000;33:216-223.
80. Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. *Liver* 2000;20:346-348.
81. Krähenbühl S, Brass EP, Hoppel CL. Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis. *Hepatology* 2000;31:1217-1223.
82. Drewe J, Krähenbühl S. Proteine für den Transport von Arzneistoffen. *Schweiz Med Wschr* 2000;130:727-731.
83. Hunger RE, Paredes BE, Quattropiani C, Krähenbühl S, Braathen LR. Primary cutaneous cryptococosis in a patient with systemic immunosuppression after liver transplantation. *Dermatology* 2000;200:352-355.
84. Vernez L, Thormann W, Krähenbühl S. Analysis of carnitine and acylcarnitines in urine by capillary electrophoresis. *J Chromatography A* 2000;895:309-316.
85. Noce R, Paredes BE, Pichler WJ, Krähenbühl S. Acute generalized pustulosis (AGEP) in a patient treated with furosemide. *Am J Med Sci* 2000; 320:331-333.
86. Lang C, Schäfer M, Serra D, Hegardt FG, Krähenbühl L, Krähenbühl S. Impaired hepatic fatty acid oxidation in rats with short-term cholestasis: characterization and mechanism. *J Lipid Res* 2001;42:22-30.
87. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J. Venooclusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. *Eur J Gastroenterol Hepatol*. 2001;13:287-90.
88. Quattropiani C, Schneider M, Helbling A, Zimmermann A, Krähenbühl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. *Liver* 2001;21:213-6.

89. Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, Krähenbühl S. Development and characterization of an animal model of carnitine deficiency. *Eur J Biochem* 2001;268:1876-1887.
90. Krähenbühl S. Mitochondria: important target for drug toxicity? *J Hepatology* 2001;34:334-336.
91. Krahenbuhl S. Alcohol-induced myopathy: What is the role of mitochondria? *Hepatology*. 2001;34:210-1.
92. Spaniol M, Bracher R, Ha HR, Follath F, Krähenbühl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. *J Hepatol* 2001;35:628-36.
93. Brooks H, Krähenbühl S. Identification and tissue distribution of two differentially spliced variants of the rat carnitine transporter OCTN2. *FEBS Letters* 2001;508:175-180.
94. Wächter S, Vogt M, Kreis R, Bösch C, Bigler P, Hoppeler H, Krähenbühl S. Long-term administration of L-carnitine to humans: effect on skeletal muscle carnitine content and physical performance. *Clin Chim Acta* 2002; 318:51-61.
95. Lang C, Schäfer M, Varga L, Zimmermann A, Krähenbühl S, Krähenbühl L. Hepatic and skeletal muscle glycogen metabolism in rats with short-term cholestasis. *J Hepatol* 2002;2002:36:22-29.
96. Schlienger RG, Keller MJ, Krähenbühl S. Tolterodine-associated acute mixed liver injury. *Ann Pharmacother* 2002;36:817-819.
97. Balmelli N, Dominé F, Pfisterer M, Krähenbühl S, Marsch S. Fatal drug interaction between cholestyramine and phenprocoumon. *Eur J Int Med* 2002;13:210-211.
98. Brooks H, Krahenbuhl S. Carnitine – transport and tissue distribution. *Recent Res Devel Biochem* 2002;3:261-286.
99. Lang C, Berardi S, Schäfer M, Serra D, Hegardt FG, Krähenbühl L, Krähenbühl S. Impaired ketogenesis is a major mechanism for disturbed hepatic fatty acid oxidation in rats with long-term cholestasis and after relief of biliary obstruction. *J Hepatol* 2002;37:564-571.
100. Meier CR, Krahenbuhl S, Schlienger RG, Jick H. Association between body mass index and liver disorders: an epidemiological study. *J Hepatol* 2002;37:741-747.
101. Mordasini MR, Krähenbühl S, Schlienger RG. Appropriateness of digoxin level monitoring. *Swiss Med Wkly* 2002;132:506-512.
102. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krahenbuhl S.

- Fulminant liver failure associated with clarithromycin. *Ann Pharmacother* 2003;37:57-60.
103. Vrtic F, Haefeli W, Drewe J, Krähenbühl S, Wenk M. Interaction of ibuprofen and probenecid with phenotyping procedures using caffeine as a probe drug. *Br J Clin Pharmacol* 2003;55:191-198.
104. Spaniol M, Kaufmann P, Beier K, Wüthrich J, Török M, Scharnagl H, März W, Krähenbühl S. Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. *J Lipid Res* 2003;44:144-153.
105. Krähenbühl L, Lang C, Lüdes S, Seiler C, Schäfer M, Zimmermann A, Krähenbühl S. Reduced hepatic glycogen stores in patients with liver cirrhosis. *Liver International* 2003;23:101-109.
106. Vernez L, Hopfgartner G, Wenk M, Krähenbühl S. Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. *J Chromatography A*;2003;984:203-213.
107. Zaugg CE, Spaniol M, Kaufmann P, Bellahcene M, Barbosa V, Tolnay M, Buser PT, Krähenbühl S. Myocardial function and energy metabolism in carnitine-deficient rats. *Cell Mol Life Sci* 2003;60:335-40.
108. Todesco L, Torok M, Krahenbuhl S, Wenk M. Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians. *Eur J Clin Pharmacol*. 2003;59:343-6
109. Affolter N, Krähenbühl S, Schlienger RG. Appropriateness of serum level determinations of antiepileptic drugs. *Swiss Med Wkly* 2003;133:591-7
110. Schnyder A, Krähenbühl S, Török M, Drewe J, Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. *Biochem J* 2004;377:61-7.
111. Wenk M, Todesco L, Krähenbühl S. Effect of hypericum extract on the activity of cyochrome P450 isoenzymes in humans. *Br J Clin Pharmacol* 2004;57:495-9.
112. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. *Ann Pharmacother* 2004;38:978-981.
113. Vernez L, Wenk M, Krähenbühl S. Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2004;18:1233-1238.

114. Rätz Bravo AE, Egger SS, Crespo S, Probst WL, Krähenbühl S. Lithium intoxication as a result of a drug-drug interaction with rofecoxib. *Ann Pharmacother* 2004;38:1189-1193.
115. Bravo AE, Drewe J, Schlienger RG, Krahenbuhl S, Pargger H, Ummenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. *Crit Care Med*. 2005;33:128-134
116. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory dyslipidemic patients treated with a statin. *Drug Safety* 2005;28:263-75.
117. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzarone induced hepatotoxicity. *Hepatology* 2005;41:925-35.
118. Delco F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dosing in patients with liver disease. *Drug Safety* 2005;28:529-45
119. Egger SS, Sawatzki MG, Drewe J, Krähenbühl S. Life-threatening hemorrhage after dalteparin in a patient with impaired renal function. *Pharmacotherapy* 2005; 25:881-5.
120. Blanco I, Krähenbühl S, Schlienger R. Corticosteroid-associated tendinopathies: An analysis of published and unpublished cases. *Drug Safety* 2005;28:633-43.
121. Schnyder A, Krähenbühl S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects. *J Drug Target* 2005;13:325-35
122. Richter B, Inderbitzin D, Lang C, Krähenbühl S, Krähenbühl L. Hepatic carbohydrate metabolism in rats after laparotomy or laparoscopy. *Surg Endosc* 2005;19:1475-82
123. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prävalenz potentieller Arzneimittel-Interaktionen bei ambulanten Patienten unter Statin-Therapie. *Praxis* 2006;95:139-46.
124. Straubhaar B, Krähenbühl S; Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. *Drug Safety* 2006;29:79-90.
125. Vernez L, Dickenmann M, Steiger J, Wenk M, Krähenbühl S. Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobatiene in long-term hemodialysis. *Nephrol Dial Transplant* 2006;21:450-8.
126. Grunder G, Zysset-Aschmann Y, Vollenweider F, Maier T, Krähenbühl S,

- Drewe J. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. *Antimicrob Agents Chemother* 2006;50:68-72.
127. Ramelli GP, Gallati S, Weis J, Krähenbühl S, Burgunder J-M. Point mutation tRNA Ser(UCN) in a child with hearing loss and myoclonus epilepsy. *J Child Neurology* 2006;21:253-5
128. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbuhl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. *Am Heart J* 2006;152:27-38
129. Beltinger J, Kaufmann P, Michot M, Terracciano L. Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide and roxithromycin. *Ann Pharmacother* 2006;40:767-70.
130. Tschambaz L, Schlatter C, Jakob M, Krähenbühl A, Wolf P, Krähenbühl S. Dose adaptation of antineoplastic drugs in patients with liver disease. *Drug Safety* 2006;29:509-522.
131. Wenk M, Droll A, Krähenbühl S. Determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006;832:313-6.
132. Wenk M, Haegeli L, Brunner HP, Krähenbühl S. Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. *J Pharm Biomed Anal* 2006;41:1367-70.
133. Bodmer M, Egger SS, Hohenstein E, Beltraminelli H, Krähenbühl S. Lichenoid drug eruption associated with the use of nebivolol. *Ann Pharmacother* 2006;40:1688-90.
134. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krähenbühl S, Chadha-Boreham H, Dingemans J. Pharmacodynamics and pharmacokinetics of the urotensin-II receptor antagonist palosuran in macroalbuminuric, diabetic patients. *Clin Pharmacol Ther* 2006;80:246-56.
135. Kaufmann P, Haschke M, Török M, Beltinger J, Bogman K, Wenk M, Terracciano L, Krähenbühl S. Mechanisms of venoocclusive disease for the combination of cyclophosphamide and roxithromycin. *Ther Drug Monit* 2006;28:766-74.
136. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. *Digestion* 2006;74:28-32.
137. Egger SS, Bachmann A, Hubmann N, Schlienger R, Krähenbühl S. Prevalence of potentially inappropriate medications in elderly patients: comparison between internal medical and geriatric wards. *Drugs Aging* 2006;23:823-37.

138. Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. *Cell Mol Life Sci* 2006;63:823-37.
139. Waldhauser KM, Török M, Ha H-R, Thomet U, Konrad D, Brecht K, Follath F, Krähenbühl S. Hepatocellular toxicity and pharmacological effects of amiodarone and amiodarone derivatives. *J Pharmacol Exp Ther* 2006;319:1413-23.
140. Porta F, Takala J, Weikert C, Kaufmann P, Krähenbühl S, Jakob SM. Effect of endotoxin, dobtamine and dopamine on muscle mitochondrial respiration in vitro. *J Endotoxin Res* 2006;12: 358-66.
141. Indermitte J, Burkholter S, Drewe J, Krähenbühl S, Hersberger KE. Risk factors associated with a high velocity to develop hyperkalemia in hospitalized patients. *Drug Safety*. 2007;30:71-80.
142. Belin GK, Krähenbühl S, Hauser PC. Direct determination of valproic acid in biological fluids by capillary electrophoresis with contactless conductivity detection. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2007;847:205-9.
143. Bottomino A, Bruppacher R, Krähenbühl S, Hersberger K. Change of body weight and lifestyle after counselling of persons at risk for type 2 diabetes: follow-up study of a screening campaign in Swiss community pharmacies. *Pharm World Sci* 2007;in press.
144. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. *Drugs Aging* 2007;24:429-40.
145. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals – a review of the recent literature. *Drug Safety* 2007;30:379-407.
146. Giger U, Büchler M, Farhadi J, Berger D, Hüsler J, Schneider H, Krähenbühl S, Krähenbühl L. Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery – a randomized controlled study. *Ann Surg Oncol* 2007;14:2798-806.
147. Link B, Haschke M, Wenk M, Krähenbühl S. Determination of midazolam and its hydroxy-metabolites in human plasma and oral fluid by liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007;21:1531-40
148. Bodmer M, Amico P, Mihatsch MJ, Haschke M, Kummer O, Krähenbühl S, Mayr M. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. *Nephrol Dial Transplant* 2007;22:2366-70.
149. Kummer O, Mossdorf E, Bodmer M, Krahenbuhl S, Battegay M, Elzi L, Haschke M. Treatment of an atazanivir-associated grade 4 hyperbilirubinemia with

- efavirenz. Gut 2007;56:1477-8.
150. Vonbach P, Dubied A, Beer JH, Krähenbühl S. Recognition and management of potential drug-drug interactions in patients on wards of internal medicine. Eur J Clin Pharmacol. 2007;63:1075-83
151. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krähenbühl S. Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol 2007;64:804-809.
152. Vonbach P, Reich R, Möll F, Krähenbühl S, Ballmer PE, Meier CR. Risk factors for gastrointestinal bleeding: a hospital-based case-control study. Swiss Med Wkly 2007;137:705-10.
153. Krähenbühl S, Brauchli Y, Kummer O, Bodmer M, Trendelenburg M, Drewe J, Haschke M. Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. Digestion 2007;75:232-237.
154. Lüde S, Török M, Dieterle S, Knapp AC, Kaeufeler R, Jäggi R, Spornitz U, Krähenbühl S. Hepatic effects of cimicifuga racemosa extract *in vivo* and *in vitro*. Cell Mol Life Sci 2007;64:2848-2857.
155. Huwyler J, Drewe J, Krähenbühl S. Tumour targeting using liposomal antineoplastic drugs. J Nanomed 2008;in press.
156. Zysset Aschmann Y, Kummer O, Linka A, Wenk A, Azzola A, Bodmer M, Krahenbuhl S, Haschke M. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with HIV protease inhibitors. Ther Drug Monit 2008;in press.
157. Knapp AC, Todesco L, Beier K, Terracciano L, Sägesser H, Reichen J, Krahenbuhl S. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J Pharmacol Exp Ther 2008;in press
158. Lüde S, Török M, Dieterle S, Jäggi R, Berger Büter K, Krähenbühl S. Hepatocellular toxicity of Kava leaf and root extracts. Phytomedicine 2008;15:120-31.
159. Bodmer M, Link B, Grignaschi N, Kummer O, Ruegg S, Haschke M, Krahenbuhl S. Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. Ther Drug Monit 2008;in press.
160. Brauchli YB, Gittermann M, Michot M, Krähenbühl S, Gnehm HP. A fatal tick bite occurring during the course of tick-borne encephalitis vaccination. Pediatr Infect Dis J. 2008;in press.
161. Brauchli YB, Scholer A, Schwietert M, Krähenbühl S. Undetectable phenytoin levels in a patient with monoclonal IgM λ . Clin Chim Acta 2008;in press.

162. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. *Eur J Int Med* 2008;in press.
163. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. *Pharm World Sci* 2008;in press.

Articles without Peer Review

1. Krähenbühl S. Pharmakokinetische und pharmakodynamische Besonderheiten im Alter: Bedeutung für die Therapie mit Psychopharmaka. *Moderne Geriatrie* 1994;10:218-228.
2. Krähenbühl S. Pharmakokinetische und dynamische Besonderheiten der medikamentösen Therapie in der Geriatrie. *Geriatrie Praxis* 1995;6:33-39.
3. Krähenbühl S. Carnitin: Vitamin oder Doping ? *Therapeutische Umschau* 1995;52:687-692.
4. Meier C, Hess C, Meier-Abt PJ, Krähenbühl S. Effects of cisapride on the function of the urinary bladder. *Schweiz Rundsch Med Prax* 1996;85:62-64.
5. Kind B, Fattinger K, Krähenbühl S, Meier-Abt PJ. Medikamentös bedingtes Angioödem. *Schweiz Rundsch Med Prax* 1996;85:567-569.
6. Kind B, Krähenbühl S, Wyss PA, Meier-Abt PJ. Dosierung von N-Acetylcystein bei akuter Vergiftung mit Paracetamol. *Schweiz Rundsch Med Prax* 1996;85:935-938.
7. Kind B, Fattinger K, Krähenbühl S, Meier-Abt PJ. Serotoninwiederaufnahmehemmer und 5-HT₃-Rezeptor-Antagonisten: gibt es klinisch relevante Interaktionen ? *Schweiz Rundsch Med Prax* 1996;85:1490-1492.
8. Krähenbühl S. Welche Analgetika wann einsetzen ? *Medical Tribune* 1996;Suppl17:20-23.
9. Fattinger K, Braunschweig S, Reichen J, Meier-Abt PJ, Krähenbühl S. Leberschädigung unter Tuberkulostatika-Behandlung. *Schweiz Rundsch Med Prax* 1997;86:626-629.
10. Krähenbühl S. Konsequenzen der Cholestase aus der Sicht des Hepatologen. *Schweiz Med Wschr* 1997;127:821-828.
11. Krähenbühl S. Physiologische Grundlagen für die Anwendung von Carnitin in der Kardiologie. *Schweiz Rundsch Med Prax* 1998;87:102-107.
12. Krähenbühl S. Anpassen der Dosierung von Medikamenten bei Patienten mit

- Nieren- und Leberinsuffizienz. Schweiz Med Wschr 1998;128:189-194.
13. Krähenbühl S, Reichen J. Prescribing in patients with liver cirrhosis. *Medicine* 1998;26:23-26.
 14. Krähenbühl S. Medikamentendosierung bei Patienten mit Nieren- oder Leberinsuffizienz. *Moderne Geriatrie* 1999;10:26-33.
 15. Krähenbühl S. Pharmakotherapie bei älteren Patienten: Problematik und Lösungsstrategien. *Medical Tribune*. 2000; 20 (Suppl):10-12.
 17. Krähenbühl S. L-carnitine and vegetarianism. *Ann Nutr Metab* 2000;44:81-82.
 18. Krähenbühl S. L-carnitine and physical performance. *Ann Nutr Metab* 2000;44:84-86.
 19. Krähenbühl S. Cytochrom P450 oder Plasmaproteine: Klinische Bedeutung für unerwünschte Arzneimittelinteraktionen. *Kliniker* 2001;30:54-58.
 20. Eich G, Krähenbühl S, Flückiger U. Nasalflu Berna: intranasaler, inaktivierter Grippeimpfstoff. *Forum Med Suisse* 2001;1:260-262.
 21. Krähenbühl S. Therapie der arteriellen Hypertonie bei älteren Patienten. *Geriatrie Praxis* 2001;12:29-33.
 22. Krähenbühl S, Reichen J. Prescribing in patients with liver cirrhosis. *Medicine* 2002;30:24-27.
 23. Krähenbühl S. Abuse of benzodiazepines and related substances. *Therapeutische Umschau* 2003;60:335-340
 24. Krähenbühl S. Dosisangleichung bei Niereninsuffizienz und Nierenersatzverfahren. *Eur J Hosp Pharmacy* 2004;10:24-27
 25. Krähenbühl S. Toxische Leberschäden. *Therapeutische Umschau* 2004;61:529-534.
 26. Krähenbühl S. Pharmakokinetik und -dynamik im Alter. *Schweiz Rundsch Med Prax* 2004;93:1305-1310.
 27. Egger SS, Schlienger RG, Krähenbühl S. Vorgehen bei unerwünschten Arzneimittelwirkungen. *Schweiz Med Forum* 2005;5:292-6
 28. Krähenbühl A, Krähenbühl S. Arzneimittelsicherheit im Spital: Medikationsfehler und unerwünschte Arzneimittelwirkungen. *Schweiz Rundsch Med Prax* 2005;94:1031-8.
 29. Krähenbühl S. Arzneimittelinteraktionen mit Statinen. *Med.Pharm.Drog.Hosp.* 2005;4:5-8.

30. Egger SS, Krähenbühl S, Schlienger R. Umgang mit unerwünschten Arzneimittelwirkungen in der zahnärztlichen Praxis. Schweiz Monatsschr Zahnmed 2005;115:1209-1213
31. Becker C, Hvalic C, Krähenbühl S, Schlienger R. Wiederholte akute Pankreatitis unter Pravastatin-Therapie. Schweiz Rundsch Med Prax 2006;95:111-116.
32. Todesco L, Waldhauser K, Krähenbühl S. Mitochondrial toxicity of drugs. Chimia 2006;60:37-39
33. Lampert ML, Krähenbühl S, Hersberger K, Schlienger RG. Clinical pharmacy and pharmaceutical care: patient-oriented application of pharmaceutical expertise. Chimia 2006;60:58-61
34. Egger SS, Gehrig Studer I, Rätz Bravo AE, Krähenbühl S. Minocyclin-induzierter Lupus erythematoses. Schweiz Rundsch Med Prax 2006;95:1155-61
35. Kummer O, Haschke M, Tuchscherer D, Lampert M, Martius F, Krähenbühl S. Agranulozytose bei einem mit Metimazol und Clopidogrel behandelten Patienten. Schweiz Rundsch Med Prax 2006;95:1297-1303.
36. Krähenbühl S. Mit Mangelernährung assoziierte Medikamente: ein Problem im Alter? Schweizer Zeitschrift für Ernährungsmedizin 2006;5:22-27
37. Krähenbühl S. Therapie mit Opiaten bei geriatrischen Patienten. Geriatrie Praxis 2007;1:18-24.
38. Kummer O, Krähenbühl S, Haschke M. Generika in der Praxis: kleine aber beachtenswerte Unterschiede. medArt 2007;17-19.
39. Krähenbühl S. Pharmakotherapie in den letzten 40 Jahren: Rückblick und Ausblick. Medical Tribune 2007;40(26):24-27
40. Kummer O, Novakova K, Burkhard T, Hamman F, Krähenbühl S, Bodmer M. Medikamentös-induzierte mikroskopische Kolitis. Schweiz Rundsch Med Prax 2007;96:1293-1297.

Book chapters

1. Reichen J, Krähenbühl S, Wirth HP, Maier KP. Liver function in cholestatic liver disease: a critical appraisal. In: Bile acids and the hepatobiliary system: from basic science to clinical practice. 68th Falk Symposium. Paumgartner G, Stiehl A, Gerok W, editors. Dordrecht: Kluwer. 1993; 258-270.
2. Reichen J, Krähenbühl S, Zimmermann H. Impact of cholestasis on hepatic function: retention of cholephiles and their potential targets. In: Cholestasis.

- Excerpta Medica. Gentilini P, Arias IM, McIntyre N, Rodés J, editors. Elsevier Science B.V. 1994;167-175.
3. Krähenbühl S, Follath F. Pharmakotherapie im Alter. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 1996;168-171.
 4. Krähenbühl S, Meier C, Krähenbühl A, Meier-Abt PJ. Unerwünschte Wirkungen von Arzneimitteln. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 1996;39-104.
 5. Krähenbühl S, Kaplowitz N. Drug-induced hepatotoxicity. In: Acute and chronic liver diseases: Molecular biology and clinics. Schmid R, Bianchi L, Blum HE, Gerok W, Maier KP, Stalder GA, editors. Kluwer Academic Publishers 1996;147-158.
 6. Krähenbühl S, Krähenbühl L. Mitochondrial dysfunction associated with chronic cholestasis. In: Cholestatic liver disease. 102th Falk Symposium. Manns MP, Boyer JL, Jansen PLM, Reichen J, editors. Dordrecht: Kluwer. 1998;107-116.
 7. Krähenbühl S. Patienten mit Organerkrankungen. In: Lehrbuch der Klinischen Pharmakologie. Jaehde U, Radziwill R, Mühlebach S, Schunack W, editors. Stuttgart: Wissenschaftliche Verlagsgesellschaft. 1998;297-310.
 8. Krähenbühl S, Mühlebach S. Variabilität der Arzneimitteltherapie. In: Lehrbuch der Klinischen Pharmakologie. Jaehde U, Radziwill R, Mühlebach S, Schunack W, editors. Stuttgart: Wissenschaftliche Verlagsgesellschaft. 1998;141-145.
 9. Krähenbühl S, Reichen J. Drug hepatotoxicity. In: Liver disease. Diagnosis and Management. Bacon BR, Di Bisceglie AM, editors. New York, Edinburgh, London. Churchill Livingstone. 2000;294-309.
 10. Krähenbühl-Melcher A, Schlienger R, Krähenbühl S. Unerwünschte Wirkungen von Medikamenten. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2001;58-135.
 11. Krähenbühl S, Follath F. Pharmakotherapie im Alter. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2001;235-41.
 12. Krähenbühl S. Pathophysiologie der Gallensekretion und Motilität der Gallenwege. In: Viszeralchirurgie. Siewert, Harder, Rothmund, editors. Springer Verlag. 2002;641-645.
 13. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: Medizinische Therapie in Klinik und Praxis. J. Schölmerich. Springer-Verlag. 2003;25-33.
 14. Krähenbühl S. Adverse effects and drug-drug interactions. In: Pharmacotherapy of obesity. Hofbauer KG, Keller U, Boss O, editors. CRC Press. 2004;285-296.

15. Wenk M, Drewe J, Krähenbühl S. Abteilung für Klinische Pharmakologie & Toxikologie am Universitätsspital Basel. Philippu A, editor. Geschichte und Wirken der pharmakologischen, klinisch-pharmakologischen und toxikologischen Institute im deutschsprachigen Raum. Berenkamp. 2004;40-46.
16. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: Medizinische Therapie in Klinik und Praxis. J. Schölmerich. 2. Auflage. Springer-Verlag. 2005;23-30.
17. Schlatter C, Krähenbühl S. Dosisanpassung bei Leberkrankheiten. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;6-13.
18. Egger SS, Schlienger RG, Krähenbühl S, Stoller R, Fattinger K. Unerwünschte Wirkungen von Arzneistoffen. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;54-148.
19. Drewe J, Krähenbühl S. Klinisch relevante Entzugssyndrome. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;244-7.
20. Krähenbühl S, Follath F. Pharmakotherapie im Alter. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;269-73.
21. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: Medizinische Therapie. J. Schölmerich. 3. Auflage. Springer-Verlag. 2007;25-33.